Equities analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce sales of $40.82 million for the current quarter, according to Zacks. Two analysts have made estimates for OraSure Technologies’ earnings, with the lowest sales estimate coming in at $40.50 million and the highest estimate coming in at $41.14 million. OraSure Technologies posted sales of $32.25 million in the same quarter last year, which suggests a positive year over year growth rate of 26.6%. The business is expected to announce its next quarterly earnings report after the market closes on Wednesday, November 1st.

On average, analysts expect that OraSure Technologies will report full year sales of $40.82 million for the current financial year, with estimates ranging from $153.50 million to $154.88 million. For the next financial year, analysts anticipate that the firm will report sales of $171.47 million per share, with estimates ranging from $170.00 million to $172.95 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million for the quarter, compared to the consensus estimate of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.07 earnings per share.

A number of equities research analysts have commented on the stock. Canaccord Genuity lifted their target price on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Jefferies Group LLC boosted their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Finally, Stephens reissued an “overweight” rating and set a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.04.

In related news, CFO Ronald H. Spair sold 510,112 shares of OraSure Technologies stock in a transaction on Monday, August 7th. The shares were sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now owns 208,606 shares in the company, valued at approximately $4,309,799.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 717,601 shares of company stock worth $14,977,398. 6.40% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OSUR. BlackRock Inc. lifted its stake in shares of OraSure Technologies by 127,593.4% during the 1st quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after buying an additional 7,737,261 shares in the last quarter. Daruma Capital Management LLC lifted its stake in shares of OraSure Technologies by 2,761.0% during the 2nd quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after buying an additional 2,722,886 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of OraSure Technologies by 30.3% during the 1st quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after buying an additional 1,037,439 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of OraSure Technologies by 127.2% during the 1st quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after buying an additional 881,132 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of OraSure Technologies by 32.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after buying an additional 452,642 shares in the last quarter. Institutional investors own 92.07% of the company’s stock.

Shares of OraSure Technologies (NASDAQ:OSUR) opened at 21.57 on Friday. The stock has a market cap of $1.28 billion, a P/E ratio of 39.87 and a beta of 1.55. The firm’s 50 day moving average price is $21.76 and its 200 day moving average price is $17.52. OraSure Technologies has a 52-week low of $7.09 and a 52-week high of $23.01.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/15/brokerages-anticipate-orasure-technologies-inc-osur-will-announce-quarterly-sales-of-40-82-million.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.